TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3207544
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg by mouth 8‐14 h and 50 mg i.m. 90 min before surgery
Study: 3207544
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg i.m. 6‐hourly with a single preinduction dose of sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Study: 3207544
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Study: 28679524
Drug: rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin treatment for 12 months
Study: 25788006
Drug: Monosodium glutamate/isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate/isotonic saline (MSG/IS) injection in TMJ
Study: 25788006
Drug: Monosodium glutamate/isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter
Study: 25788006
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IS) injection in masseter
Study: 25788006
Drug: Monosodium glutamate/isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter and TMJ
Study: 25788006
Drug: Painful masseter
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful masseter injection
Study: 25788006
Drug: Painful TMJ
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful TMJ injection
Study: 17903498
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic epidural analgesia with 0.2% ropivacaine containing 2 microg/mL fentanyl
Study: 17903498
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia with morphine
Study: 12357520
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 32 cc
Study: 12357520
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 40 cc
Study: 734578
Drug: Segmental epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental epidural block with lower dosages of bupivacaine; specific dosage not mentioned; technique involved patients kneeling on all fours.
Study: 30676045
Drug: Brief Warrior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Warrior Renew treatment (8 sessions)
Study: 25638038
Drug: Tailored, personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored, personalized site (treatment)
Study: 19357698
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and HCTZ 25 mg
Study: 19357698
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg and HCTZ 25 mg
Study: 11340684
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human DNase (rhDNase)
Study: 30154254
Drug: Stent retriever
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent retriever (SR) treatment with SVS present
Study: 30154254
Drug: Stent retriever
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent retriever (SR) treatment without SVS
Study: 23925452
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 400 mg/day)
Study: 21830049
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of sevoflurane based on SEDLine™ data
Study: 17910221
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without application of a desensitizing agent)
Study: 17910221
Drug: Fluor Protector
Normalized name: Fluor a Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluor Protector (desensitizing treatment)
Study: 17910221
Drug: VivaSens (desensitizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: VivaSens (desensitizing treatment)
Study: 17910221
Drug: Isodan (desensitizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isodan (desensitizing treatment)
Study: 17910221
Drug: Futura Bond
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futura Bond NR (desensitizing treatment)
Study: 17910221
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser (desensitizing treatment)
Study: 15133865
Drug: Bifid triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifid triple viable capsule (BIFICO) (1.26 g/d)
Study: 8333941
Drug: 1% fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% fusidic acid viscous eye drops, self-administered four times daily for seven days before surgery
Study: 8333941
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert ophthalmic drops)
Study: 3080285
Drug: misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol (200 micrograms four times daily) with tolmetin (2000 mg/day, in four divided doses)
Study: 3080285
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with tolmetin (2000 mg/day, in four divided doses)
Study: 24206547
Drug: Intermittent Boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Boluses (IB) - 20 mg propofol boluses on demand
Study: 24206547
Drug: Pump Continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump Continuous Infusion (PCI) - 3 mg/kg/h plus 20 mg boluses on demand
Study: 19593179
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract therapy
Study: 17229901
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (40 g soy protein, 118 mg isoflavones)
Study: 12774015
Drug: Amantadine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine group (amantadine sulphate 100 mg twice daily orally)
Study: 18656314
Drug: Daily smokers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smokers
Study: 9216458
Drug: Weekly alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alcohol consumption
Study: 8267669
Drug: Oxerutins (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutins (900 mg/day for 12 weeks)
Study: 8267669
Drug: Troxerutin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin (900 mg/day for 12 weeks)
Study: 29569219
Drug: Cabergoline (D2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (D2-receptor agonist)
Study: 23840645
Drug: Wake therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wake therapy (sleep deprivation) combined with light therapy and sleep time stabilisation
Study: 2554630
Drug: Desferrioxamine B
Normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine B 500 mg intravenously followed by packed red cell transfusion
Study: 782774
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg/70 kg
Study: 782774
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg/70 kg
Study: 782774
Drug: Butorphanol 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 4 mg/70 kg
Study: 782774
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg/70 kg
Study: 782774
Drug: Meperidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 80 mg/70 kg
Study: 30415628
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (2 g twice daily, total daily dose 4 g)
Study: 29925712
Drug: 1% malic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% malic acid spray
Study: 26572686
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg once daily plus PegIFN/RBV for 24 weeks
Study: 22229837
Drug: Transdermal sumatriptan
Normalized name: sumatriptan Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal sumatriptan
Study: 14722645
Drug: 0.28 g
Normalized name: DIBUCAINE 0.28 g in 28 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.28 g of glutamine per kg bodyweight per day intravenously for five days
Study: 14722645
Drug: 0.57 g
Normalized name: OATMEAL 0.57 g in 0.57 g TOPICAL SALVE [Superbalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.57 g of glutamine per kg bodyweight per day intravenously for five days
Study: 14722645
Drug: 0.86 g
Normalized name: MENTHOL, UNSPECIFIED FORM 0.86 g in 1 g ORAL LOZENGE [Menthol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.86 g of glutamine per kg bodyweight per day intravenously for five days
Study: 14722645
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of glutamine per kg bodyweight per day intravenously for five days (control)
Study: 12201937
Drug: ESWL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL with diuresis (i.v. infusion of 500 ml normal saline containing 40 mg furosemide)
Study: 9653697
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of azithromycin
Study: 9653697
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of azithromycin (for patients)
Study: 8581842
Drug: Local nasal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nasal immunotherapy (LNIT) with allergen in powder form
Study: 2523787
Drug: Metformin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.5 g x 3 daily)
Study: 1261583
Drug: Verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1 mg/kg i.v.)
Study: 795700
Drug: Dipyridamol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamol (20 mg i.v.)
Study: 795700
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml saline i.v.)
Study: 24113028
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 100 mg enteric-coated aspirin
Study: 21437676
Drug: Operational multidisciplinary
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operational multidisciplinary antibiotic team
Study: 11541691
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TAS)
Study: 11541691
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered promethazine
Study: 31284424
Drug: Partly fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partly fermented infant formula with 30% fermented formula and 0.8 g/100 mL scGOS/lcFOS
Study: 23079125
Drug: MTX 7.5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX 7.5‐20 mg/week + cyclosporine (CYA) 2.5‐4 mg/kg (combination)
Study: 23079125
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + placebo-CYA (monotherapy)
Study: 20659915
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg kg(‐1) (maximum 10 mg)
Study: 16251562
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of 0.2% hypobaric tetracaine
Study: 16251562
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of 0.2% hypobaric tetracaine
Study: 16251562
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg of 0.2% hypobaric tetracaine
Study: 12087923
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of nifedipine in the test preparation 'XL' (Nifecard)
Study: 12087923
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of nifedipine in the reference formulation 'LA'
Study: 1416009
Drug: Sprotte 24
Normalized name: BRUSSELS SPROUT
DrugBank: Brussels sprout (DB10642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprotte 24 G needle (n = 28)
Study: 1416009
Drug: Vygon 29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vygon 29 G needle (n = 28)
Study: 3890228
Drug: Gentamicin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (280 mg, single dose, intramuscularly)
Study: 3890228
Drug: Kanamycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin (2 g, single dose, intramuscularly)
Study: 26978136
Drug: Subfascial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subfascial administration of 3 g of tranexamic acid (TXA)
Study: 24650447
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 µg) plus Formoterol (12 µg)
Study: 24650447
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 µg) plus Doxofylline (400 mg)
Study: 24650447
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 µg) plus Montelukast (10 mg)
Study: 24650447
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 µg) plus Tiotropium (18 µg)
Study: 22810981
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (1 mg/d)
Study: 20571496
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) supplementation (100 mg/day) plus 5 mg/day folic acid
Study: 20571496
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 mg/day folic acid only)
Study: 18055960
Drug: Postcard intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcard intervention (plus treatment as usual)
Study: 16032446
Drug: High-dose buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose buprenorphine (BH group)
Study: 16032446
Drug: Low-dose buprenorphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose buprenorphine (BL group)
Study: 11878655
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + NSAID
Study: 10438047
Drug: HbNOMP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbNOMP vaccine
Study: 2341658
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon alpha 2b gel (30 million IU/gm), applied 4 times a day for 4 weeks
Study: 2341658
Drug: Placebo preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation, applied 4 times a day for 4 weeks
Study: 6989438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplements (ergocalciferol, 1000 IU/day)
Study: 31744313
Drug: Local Corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Corticosteroid Injection (LCI)
Study: 23356886
Drug: 14-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Study: 23356886
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Study: 20966907
Drug: Parent-only (PO)
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-only (PO) treatment
Study: 20966907
Drug: Parent +
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent + child (PC) treatment
Study: 8156447
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with Dermatophagoides pteronyssinus at high doses
Study: 3264709
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Study: 3264709
Drug: Thiamylal 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 4.0 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Study: 31321928
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose first (AB sequence)
Study: 31321928
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose first (BA sequence)
Study: 27476354
Drug: Ibuprofen (Control)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Control)
Study: 20721883
Drug: Taribavirin (TBV)
Normalized name: Ribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin (TBV) 20 mg/kg/day
Study: 20721883
Drug: Taribavirin (TBV)
Normalized name: Ribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin (TBV) 25 mg/kg/day
Study: 20721883
Drug: Taribavirin (TBV)
Normalized name: Ribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin (TBV) 30 mg/kg/day
Study: 20721883
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) 800-1400 mg/day
Study: 10540659
Drug: Pulsed spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed spray
Study: 9005788
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once a day for 7 to 14 days (average 11 days), administered intravenously for the first 3-5 days and then orally
Study: 8695563
Drug: Prophylactic surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic surfactant treatment
Study: 8695563
Drug: Rescue surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue surfactant treatment
Study: 2007937
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (both prophylactic and rescue)
Study: 369009
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution irrigation (Control)
Study: 30786157
Drug: Melatonin 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.075 mg/kg (maximum 5 mg)
Study: 30786157
Drug: Melatonin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.15 mg/kg (maximum 10 mg)
Study: 30786157
Drug: Melatonin 0.3
Normalized name: melatonin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.3 mg/kg (maximum 20 mg)
Study: 30786157
Drug: Melatonin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (all dose levels)
Study: 18757193
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy
Study: 28575414
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously, twice weekly
Study: 23636036
Drug: Perennial immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perennial immunotherapy (PIT)
Study: 23636036
Drug: Preseasonal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal immunotherapy (PSIT)
Study: 15082209
Drug: 2-stage implant
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage implant
Study: 15082209
Drug: 1-stage implant
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-stage implant
Study: 9924848
Drug: Furosemide/morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide/morphine
Study: 7999403
Drug: Anti-emetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-emetic treatment (specifics not provided)
Study: 3186615
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg sustained release tablets once daily
Study: 3186615
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg conventional tablets administered twice daily
Study: 29562260
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist trigger followed by specialized regimen (1500 IU hCG) at time of oocyte retrieval plus oral estradiol and intramuscular progesterone during luteal phase
Study: 29562260
Drug: hCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG trigger (5000 IU) with luteal support (oral estradiol and vaginal progesterone)
Study: 28252533
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy (arm A)
Study: 28252533
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy plus cetuximab (arm B)
Study: 21467190
Drug: Tramadol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50, 100, 200, and 400 mg)
Study: 21467190
Drug: Hydromorphone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (4 and 8 mg)